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Abstract
Obesity is an important component of metabolic syndrome X and predisposes to the development
of type 2 diabetes mellitus. The incidence of obesity, type 2 diabetes mellitus and metabolic
syndrome X is increasing, and the cause(s) for this increasing incidence is not clear. Although
genetics could play an important role in the higher prevalence of these diseases, it is not clear how
genetic factors interact with environmental and dietary factors to increase their incidence. We
performed gene expression profile in subjects with obesity and type 2 diabetes mellitus with and
without family history of these diseases. It was noted that genes involved in carbohydrate, lipid and
amino acid metabolism pathways, glycan of biosynthesis, metabolism of cofactors and vitamin
pathways, ubiquitin mediated proteolysis, signal transduction pathways, neuroactive ligand-
receptor interaction, nervous system pathways, neurodegenerative disorders pathways are
upregulated in obesity compared to healthy subjects. In contrast genes involved in cell adhesion
molecules, cytokine-cytokine receptor interaction, insulin signaling and immune system pathways
are downregulated in obese. Genes involved in signal transduction, regulation of actin cytoskeleton,
antigen processing and presentation, complement and coagulation cascades, axon guidance and
neurodegenerative disorders pathways are upregulated in subjects with type 2 diabetes with family
history of diabetes compared to those who are diabetic but with no family history. Genes involved
in oxidative phosphorylation, immune, nervous system, and metabolic disorders pathways are
upregulated in those with diabetes with family history of diabetes compared to those with diabetes
but with no family history. In contrast, genes involved in lipid and amino acid pathways, ubiquitin
mediated proteolysis, signal transduction, insulin signaling and PPAR signaling pathways are
downregulated in subjects with diabetes with family history of diabetes. It was noted that genes
involved in inflammatory pathway are differentially expressed both in obesity and type 2 diabetes.
These results suggest that genes concerned with carbohydrate, lipid and amino acid metabolic
pathways, neuronal function and inflammation play a significant role in the pathobiology of obesity
and type 2 diabetes.
Introduction
Metabolic syndrome X is characterized by (a) abdominal
obesity, (b) atherogenic dyslipidemia, (c) raised blood
pressure, (d) insulin resistance with or without glucose
intolerance, (e) pro-inflammatory state, and (f) pro-
thrombin state. Thus, subjects who have abdominal obes-
ity, atheroslcerosis, insulin resistance and
hyperinsulinemia, hyperlipidemias, endothelial dysfunc-
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tion, essential hypertension, type 2 diabetes mellitus, and
coronary heart disease (CHD) are considered to have met-
abolic syndrome X. Other features of metabolic syndrome
X also include: hyperfibrinogenemia, increased plasmino-
gen activator inhibitor-1 (PAI-1), low tissue plasminogen
activator, nephropathy, micro-albuminuria, and hyperu-
ricemia. The incidence of metabolic syndrome X is
increasing, and the cause(s) for this increasing incidence
is not clear. Although genetics could play an important
role in the higher prevalence of metabolic syndrome X, it
is not clear how genetic factors interact with environmen-
tal and dietary factors to increase its incidence. Since obes-
ity and type 2 diabetes mellitus occur together and can run
in families, it will be interesting to study gene expression
profiles in subjects who have obesity and type 2 diabetes
mellitus with and without family history to know the role
of genetics in the pathobiology of these two diseases.
Obesity is a low-grade systemic inflammatory condition
[1,2]. Plasma levels of C-reactive protein (CRP), tumor
necrosis factor-α (TNF-α), and interleukin-6 (IL-6), mark-
ers of inflammation are elevated in subjects with obesity,
insulin resistance, essential hypertension, type 2 diabetes,
and CHD both before and after the onset of these diseases
[3-9]. Overweight children and adults showed an increase
in CRP concentration compared with normal weight chil-
dren [3]. In these subjects, a direct correlation between the
degree of adiposity and plasma CRP levels was noted. Ele-
vated CRP concentrations has been shown to be associ-
ated with increased risk for CHD, ischemic stroke,
peripheral arterial disease, and ischemic heart disease
mortality in healthy men and women. A strong relation
between elevated CRP levels and cardiovascular risk fac-
tors: fibrinogen, and HDL cholesterol was also reported.
Furthermore, weight reduction and/or exercise decrease
serum concentrations of TNF-α and simultaneously a
reduction in the risk of CHD is also noted. This is sup-
ported by the observation that a negative correlation exists
between plasma TNF-α and HDL cholesterol, glycosylated
hemoglobin, and serum insulin concentrations that could
explain as to why CHD is more frequent in obese com-
pared to healthy or lean subjects [3,9]. Despite these evi-
dences showing the relationship between inflammatory
markers and obesity, type 2 diabetes mellitus, and CHD,
the exact genetic relationship between these diseases is
not clear. Hence in the present study, we performed gene
expression profile in subjects with obesity and type diabe-
tes mellitus with and without family history.
Materials and methods
Blood samples were obtained from 6 subjects. Of which:
one was a healthy normal (H), one was healthy but was
overweight (HO), one was obese (O), two were having
type diabetes with no family history of diabetes (DNPH:
DNPH1 and DNPH2), and one had type 2 diabetes whose
parents were also diabetic (DPH). All these subjects were
matched for age, gender, and body mass index. RNA was
extracted from the peripheral blood leukocytes from these
subjects, hybridized on Human 40K OciChip array (Oci-
mum Biosolutions, Hyderabad, India). Gene expression
values were obtained after quantification of TIFF images.
Data has 40,320 × 6 data points. Empty spots and control
probes were removed before proceeding with data analy-
sis. This study was approved by the Ethics Committee of
Andhra University, Visakhapatnam, India., and the con-
sent of all the participants was obtained.
Analysis performed
The data obtained was analyzed by two methods: (a) Dif-
ferential expression analysis, and (b) Functional classifi-
cation of differentially expressed genes.
Differential expression analysis
The primary objective of the study of gene expression pro-
files using microarray is to assess the mRNA transcript lev-
els of samples under different experimental conditions
and detect significant difference in expression levels of
various genes across samples. When the number of repli-
cates for each condition is adequate, the identification of
differentially expressed genes is meaningful. However, in
majority of instances, there are no or limited replicates
due to practical constraints of cost and feasibility. In such
an instance, appropriate statistical techniques are per-
formed to arrive at information on differentially expressed
genes.
For experiments with single sample in different condi-
tions, it is assumed that the log intensity values of gene
expression for the two samples are linearly related, follow-
ing bivariate normal distribution, contaminated with out-
liers. In a contaminated bivariate distribution, the main
body of the data is characterized by bivariate normal dis-
tribution and constitutes regular observations. The non-
regular observations, described as outliers, represent sys-
tematic deviations. These outliers are often suspected as
possible candidates for differential expression genes
[10,11]. We have used this approach consisting of two-
stages to detect outliers from bivariate population and
determining differentially expressed candidate genes from
these outliers. This approach provides the fold-change
value considering the scatter of observations and thereby
provides up and down regulated genes across the samples.
Methodology of analysis of data
Multivariate outlier detection
Outlier detection is one of the important tasks in any data
analysis, which describes abnormalities in the data. Many
methods have been proposed in the literature for detect-
ing univariate outliers based on robust estimation of loca-
tion and scale parameters [12-14]. The standard methodLipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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for multivariate outlier detection involves robust estima-
tion of parameters in the Mahalanobis distance (MD)
measure and then comparing MD with the critical value of
X2 distribution. The values larger than the critical value are
treated as outliers of the distribution.
Mahalanobis distance
The shape and the size of multivariate data are quantified
by the covariance matrix, which is taken into account in
the Mahalanobis distance. Thus, for a multivariate sample
Xij, where i = 1, 2, 3,... n (number of genes) and j = 1, 2,
3... p (number of samples), the Mahalanobis distance is
defined as,
MD1 = ((xij-m)TC-1(xij-m))0.5 (1)
where m is the estimated multivariate location parameter
and C is the estimated covariance matrix. For multivariate
normal data, the squared MD values are approximately
chi-square distributed with p degrees of freedom. Multi-
variate outliers can now be defined as the observations
having large (squared) MD values. A quantile for a chi-
square distribution can be fixed (say 95%) and the obser-
vations with MD values greater than the chi-square cut-off
at 95% are considered as outliers. The location and the
covariance parameters are estimated using robust estima-
tion methods. One of the well-known methods of estima-
tion viz. Minimum Covariance Determinant (MCD) has
been used in the study.
Minimum covariance determinant (MCD)
The MCD estimator is determined by that subset of obser-
vations of size h, which minimizes the determinant of the
covariance matrix computed only from the h  observa-
tions. The location estimator is the average of these h
observations, whereas the scatter estimate is proportional
to the variance covariance matrix. As a compromise
between robustness and efficiency, usually h = 0.75n (n is
the sample size) is used in the analysis. The distances
obtained after using robust estimators are referred as
robust distances (RD). Rousseeuw and Van Zomeren [15]
have used these RDs for multivariate outlier detection,
such that if the squared RD for an observation is larger
than the cut-off, say χ2
p;97.5%' it can be declared as an out-
lier.
The location and scale parameters of the scatter can be
obtained using MCD and accordingly the robust distance
(RD) for each observation (gene) could be obtained using
equation (1). An empirical distribution function (EDF) is
obtained for RD, which is compared with the chi-square
distribution function for two degrees of freedom. For mul-
tivariate normally distributed data, the empirical distribu-
tion converges to the theoretical one. Hence, the tails of
the distribution are often compared for detecting outliers.
The tails will be defined by small δ = χ2
p;1-α for a certain
small α (say 0.05). The vertical line in the figure indicates
the cut-off value of chi-square for two degrees of freedom
for 95% quantile. The observations with RD values greater
than the cut-off are declared as outliers. Upon identifying
the bivariate outliers, the next task is to identify those out-
lier genes that are differentially expressed across the two
samples. The stage II level analysis deals with identifying
a set of outlying genes that are differentially expressed.
Stage II: Univariate outliers detection
The univariate outliers detection analysis is performed as
follows:
Let S denote the original set of observations. Let Sout and
Sin be the subsets of S containing outlier and inlier obser-
vations respectively. Thus,
Sout ∪ Sin = S and Sout ∩ Sin = {∅}, i.e. the two subsets are
mutually exclusive.
We denote:
Sout = {(log2(Xi1), log2(Xi2))/MDi > c for I = 1, 2, 3..... n}
and
Sin = {(log2(Xi1), log2(Xi2))/MDi ϕ c for I = 1, 2, 3..... n}
where 'c' is the cut-off for a given quantile and n is the
total number of genes.
We define a statistic,
which is the log of the ratio of intensity values for different
genes for the two samples. Here X1 is treated as reference,
while X2 is treated as test sample. The statistic provides a
measure of differential expression (DE) of genes across
the samples. The genes showing at least k-fold change
(usually k = 2, i.e. Z = 1) across the samples are considered
to be DE genes. The appropriate choice of k is important
since it influences the number of DE genes. Here we pro-
pose a rationale for selecting k for a given percentage of
bivariate outliers.
We generate values for the statistic for the entire set as,
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For a perfect linear relationship between the two samples,
the Z statistic becomes residual following normal distri-
bution with mean m and variance Se
2'.
The statistic is used to obtain Mahalanobis distance meas-
ure as,
The transformed distance measure is supposed to follow
chi-square distribution with one degree of freedom. The
empirical distribution function of MD* could be obtained
and compared with that of the cumulative distribution of
chi-square with one degree of freedom. A cut-off could be
selected for MD* such that the observations greater than
the cut-off could be declared as outliers. We search for an
optimal cut-off, so that the univariate subset of outliers
does not include any of the bivariate inliers. In other
words, if Rout is a subset of univariate outliers and Sin the
subset of bivariate inliers of S, then the optimal cut-off
could be obtained as,
C*opt = inf[Ci*/Rout  Sin = {∅}]
The optimal cut-off could be obtained programmatically
thereby yielding a set of univariate outliers that overlap
with a subset of multivariate outliers. Figure 1 shows the
common outliers obtained by both the methods for an
optimal cut-off value of 6.15.
The probability value for this cut-off could be obtained by
referring to chi-square distribution with one degree of
freedom, which is 0.0132. Thus, 1.3% of the genes are
outliers and are differentially expressed across the two
samples. The observations indicated by green spots is the
subset of bivariate outliers, which could have been differ-
entially expressed across the samples. The cut-off value
could be used in equation (2) to obtain the z-value as,
This z-value determines the log fold change resulting into
bivariate outliers that could be the potential candidates
for differential expression. In the above case, z value is
1.31, suggests that the bivariate outliers with fold change
of 2.5 (21.31 = 2.48) and above across the samples could
be the DE candidates. Figure 2 shows thresholds for log
2.48-fold change and log 2-fold change. The log 2-fold
change includes large number of bivariate inliers, which
are eliminated by log 2.48-fold change. The observations
above log 2.48-fold are declared as up regulated with ref-
erence to X1, while those below log 0.4-fold are declared
as down regulated.
Thus, the approach described above identifies DE candi-
dates amongst those observations, which are non-regular
for some predefined percentile value and thereby provides
a rationale for selecting the k-fold change.
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The up and down regulated genes for 2.48- and 2-log fold  change thresholds Figure 2
The up and down regulated genes for 2.48- and 2-log fold 
change thresholds.
 
Outliers obtained using bivariate and univariate approaches Figure 1
Outliers obtained using bivariate and univariate approaches.
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Analysis of the data obtained in the present study
Applying these principles to the present study, in the
present context, there are six individuals, one from each of
the categories namely healthy (H), healthy with obesity
(H&O), obesity only (O), diabetes with parental history
(DPH) and two individuals having diabetes without
parental history (DNPH1 and DNPH2). The expression
levels of 39,400 genes for each individual were obtained
and compared pair wise, resulting into fifteen combina-
tions. The analysis was carried out for each of these com-
binations independently following the afore stated
approach. Prior to analysis, the data for each combination
was normalized using Loess normalization. Below we
present the analysis for each combination along with the
interpretations.
Results
1. Healthy (reference) vs. Healthy with overweight (test 
sample) [H vs HO]
In the first step, the log intensity values of the gene expres-
sion for the two samples were preprocessed using loess
method, in order to remove any measurement bias in the
experiment. Figure 3 shows the MA-plots for before and
after Loess normalization. Upon normalizing the expres-
sion values for the two samples, the scatter plot of log
intensity values was obtained as shown in Figure 4. The
scatter plot gives the bivariate distribution along with con-
taminated observations (genes)/outliers. The Mahalano-
bis distance measure was used to identify outliers for p =
0.10. Thus out of 39,400 genes, 3,940 genes were identi-
fied as outliers as indicated by red spots in Figure 5.
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 6 shows the thresholds for 2.36-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 1,247 were detected as
up regulated, while 331 were detected as down-regulated
genes with respect to the healthy (H) individual. Thus, for
healthy vs. healthy with obesity comparison, 1,578 genes
were found to be differentially expressed out of 39,400,
which amounts to 4% of the total genes under study. This
is 2.7% less than the number of genes obtained for 2-fold
change thresholds. We refer 2.36 as the modified fold
change, which is obtained based on the scatter of the dis-
tribution. More the scatter, larger is the modified fold
change, thereby reducing the number of DE genes. The up
and down regulated genes for the two categories were fur-
ther considered for Gene Ontology (GO) and pathway
analysis. On similar lines, the analysis was carried out for
the remaining fourteen comparisons and the correspond-
ing figures for each comparison are given below.
2. Healthy (reference) vs Obesity (test sample) [H vs O]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
MA-plots showing scatter of expression values before and after Loess normalization for healthy vs. healthy with obesity com- parison Figure 3
MA-plots showing scatter of expression values before and after Loess normalization for healthy vs. healthy with obesity com-
parison.
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(c*). Figure 7 shows the thresholds for 2.94-fold change,
thereby providing the up and down regulated genes. Out
of 3,940 outlier genes, 962 were detected as up regulated,
while 989 were detected as down-regulated genes with
respect to the healthy (H) individual. Thus, for healthy vs.
obesity comparison, 1,951 genes were found to be differ-
entially expressed out of 39,400, which amounts to 4.9%
The thresholds for 2.94 and 2 fold change values Figure 7
The thresholds for 2.94 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy vs. obesity comparison.
 
Bivariate outliers based on Mahalanobis distance measure for  p = 0.10 for healthy vs. healthy with obesity comparison Figure 5
Bivariate outliers based on Mahalanobis distance measure for 
p = 0.10 for healthy vs. healthy with obesity comparison.
 
Scatter plot of log intensities for healthy vs. healthy with  obesity comparison after Loess normalization Figure 4
Scatter plot of log intensities for healthy vs. healthy with 
obesity comparison after Loess normalization.
The thresholds for 2.36 and 2 fold change values Figure 6
The thresholds for 2.36 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy vs. healthy with obesity comparison.Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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of the total genes under study. This is 6% less than the
number of genes obtained for 2-fold change thresholds.
3. Healthy (reference) vs Diabetic with no parental 
history1 (test sample) [H vs DNPH1]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 8 shows the thresholds for 2.37-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 1,249 were detected as
up regulated, while 477 were detected as down-regulated
genes with respect the healthy (H) individual. Thus, for
healthy vs. diabetic with no parental history (1) compari-
son, 1,726 genes were found to be differentially expressed
out of 39,400, which amounts to 4.3% of the total genes
under study. This is 3.3% less than the number of genes
obtained for 2-fold change thresholds.
4. Healthy (reference) vs Diabetic with no parental 
history2 (test sample) [H vs DNPH2]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 9 shows the thresholds for 2.96-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 861 were detected as up
regulated, while 356 were detected as down-regulated
genes with respect to the healthy (H) individual. Thus, for
healthy vs. diabetic with no parental history [2] compari-
son, 1,217 genes were found to be differentially expressed
out of 39,400, which amounts to 3% of the total genes
under study. This is 7% less than the number of genes
obtained for 2-fold change thresholds. It can be seen from
the results depicted in Figures 8 and 9 that even though
both subjects [1 and 2] are having type 2 diabetes mellitus
with no parental history of diabetes, the genes that were
differentially expressed compared to healthy control were
slightly different between the two [1 and 2]. But, on the
whole the differentially expressed genes were similar
(compare figure 8 and 9).
5. Healthy (reference) vs Diabetic with parental history 
(test sample) [H vs DPH]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 10 shows the thresholds for 2.36-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 1,211 were detected as
up regulated, while 368 were detected as down-regulated
genes with respect to the healthy (H) individual. Thus, for
healthy vs. diabetic with parental history comparison,
1,579 genes were found to be differentially expressed out
of 39,400, which amounts to 4% of the total genes under
study. This is 2.73% less than the number of genes
obtained for 2-fold change thresholds.
6. Healthy with overweight (reference) vs Obesity (test 
sample) [HO vs O]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
The thresholds for 2.96 and 2 fold change values Figure 9
The thresholds for 2.96 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy vs. diabetic with no parental history [2] comparison.
The thresholds for 2.37 and 2 fold change values Figure 8
The thresholds for 2.37 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy vs. diabetic with no parental history [1] comparison.Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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value (c*). Figure 11 shows the thresholds for 2.38-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 814 were detected as up
regulated, while 1,469 were detected as down-regulated
genes with respect to healthy individual with overweight
(HO). Thus, for healthy with obesity vs. obesity compari-
son, 2,283 genes were found to be differentially expressed
out of 39,400, which amounts to 5.8% of the total genes
under study. This is 2.6% less than the number of genes
obtained for 2-fold change thresholds.
7. Healthy with Overweight (reference) vs Diabetic with 
no parental history1 (test sample) [HO vs DNPH1]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 12 shows the thresholds for 2.14-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 539 were detected as up
regulated, while 1,058 were detected as down-regulated
genes with respect to healthy individual with overweight
(HO). Thus, for healthy with overweight vs. diabetic with
no parental history [1] comparison, 1,597 genes were
found to be differentially expressed out of 39,400, which
amounts to 4% of the total genes under study. This is
1.2% less than the number of genes obtained for 2-fold
change thresholds.
8. Healthy with Overweight (reference) vs Diabetic with 
no parental history2 (test sample) [HO vs DNPH2]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
The thresholds for 2.14 and 2 fold change values Figure 12
The thresholds for 2.14 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy with overweight vs. diabetic with no parental history 
[1] comparison.
  
The thresholds for 2.36 and 2 fold change values Figure 10
The thresholds for 2.36 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy vs. diabetic with parental history of type 2 diabetes 
mellitus comparison.
The thresholds for 2.38 and 2 fold change values Figure 11
The thresholds for 2.38 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy with overweight s. obesity comparison.Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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value (c*). Figure 13 shows the thresholds for 2.43-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 541 were detected as up
regulated, while 672 were detected as down-regulated
genes with respect to healthy individual with obesity
(HO). Thus, for healthy with overweight vs. diabetic with
no parental history [2] comparison, 1,213 genes were
found to be differentially expressed out of 39,400, which
amounts to 3% of the total genes under study. This is
2.75% less than the number of genes obtained for 2-fold
change thresholds. When the results given in Figures 12
and 13 are compared they look very similar. This suggests
that, in general, the differentially expressed genes between
healthy with overweight vs. those with type 2 diabetes
mellitus (even when compared with two distinctly differ-
ent individuals) with no parental history are almost iden-
tical.
9. Healthy with Overweight (reference) vs Diabetic with 
parental history (test sample) [HO vs DPH]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 14 shows the thresholds for 2.07-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 502 were detected as up
regulated, while 822 were detected as down-regulated
genes with respect to healthy individual with overweight
(HO). Thus, for healthy with overweight vs. diabetic with parental history comparison, 1,324 genes were found to
be differentially expressed out of 39,400, which amounts
to 3.3% of the total genes under study. This is 0.05% less
than the number of genes obtained for 2-fold change
thresholds.
10. Obesity (reference) vs Diabetic with no parental 
history1 (test sample) [O vs DNPH1]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
(c*). Figure 15 shows the thresholds for 2.07-fold change,
thereby providing the up and down regulated genes. Out
of 3,940 outlier genes, 1,479 were detected as up regu-
lated, while 1,333 were detected as down-regulated genes
with respect the individual with obesity (O). Thus, for
obesity vs. diabetes with no parental history [1] compari-
son, 2,812 genes were found to be differentially expressed
out of 39,400, which amounts to 7.1% of the total genes
under study. This is 0.06% less than the number of genes
obtained for 2-fold change thresholds.
11. Obesity (reference) vs Diabetic with no parental 
history2 (test sample) [O vs DNPH2]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 16 shows the thresholds for 2.39-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 1,534 were detected as
The thresholds for 2.07 and 2 fold change values Figure 14
The thresholds for 2.07 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy with overweight vs. diabetic with parental history of 
diabetes comparison.
The thresholds for 2.43 and 2 fold change values Figure 13
The thresholds for 2.43 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for 
healthy with overweight vs. diabetic with no parental history 
[2] comparison. Compare these results with those in Figure 
12.Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
Page 10 of 19
(page number not for citation purposes)
up regulated, while 813 were detected as down-regulated
genes with respect the individual with obesity (O). Thus,
for obesity vs. diabetic with no parental history [2] com-
parison, 2,347 genes were found to be differentially
expressed out of 39,400, which amounts to 5.95% of the
total genes under study. This is 2.6% less than the number
of genes obtained for 2-fold change thresholds.
12. Obesity (reference) vs Diabetic with parental history 
(test sample) [O vs DPH]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 17 shows the thresholds for 2.17-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 1,338 were detected as
up regulated, while 1,002 were detected as down-regu-
lated genes with respect the individual with obesity. Thus,
for obesity vs. diabetic with parental history comparison,
2,340 genes were found to be differentially expressed out
of 39,400, which amounts to 5.93% of the total genes
under study. This is 1% less than the number of genes
obtained for 2-fold change thresholds.
13. Diabetic with no parental history1 (reference) vs 
Diabetic with no parental history2 (test sample) [DNPH1 
vs DNPH2]
Here we compared gene expression profile between two
subjects with type 2 diabetes mellitus whose parents were
also diabetic. The distribution of log fold change values
was obtained and the outliers were detected for the opti-
mum cut-off value (c*). Figure 18 shows the thresholds
for 2.18-fold change, thereby providing the up and down
The thresholds for 2.17 and 2 fold change values Figure 17
The thresholds for 2.17 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for obes-
ity vs. diabetic with no parental history comparison.
The thresholds for 2.07 and 2 fold change values Figure 15
The thresholds for 2.07 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for obes-
ity vs. diabetic with no parental history [1] of diabetes com-
parison.
The thresholds for 2.39 and 2 fold change values Figure 16
The thresholds for 2.39 and 2 fold change values. The green 
spots are the differentially expressed outlier genes for obes-
ity vs. diabetic with no parental history [2] of diabetes com-
parison.Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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regulated genes. Out of 3,940 outlier genes, 948 were
detected as up regulated, while 662 were detected as
down-regulated genes with respect to the individual with
diabetes and no parental history [1]. Thus, a comparison
between two individuals who were both diabetic with no
parental history [1 and 2], 1,610 genes were found to be
differentially expressed out of 39,400, which amounts to
4% of the total genes under study. This is 1.5% less than
the number of genes obtained for 2-fold change thresh-
olds.
14. Diabetic with no parental history1 (reference) vs 
Diabetic with parental history (test sample) [DNPH1 vs 
DPH]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 19 shows the thresholds for 2-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 686 were detected as up
regulated, while 682 were detected as down-regulated
genes with respect to the individual with diabetic and no
parental history [1]. Thus, for diabetic with no parental
history [1] vs. diabetic with parental history comparison,
1,368 were found to be differentially expressed out of
39,400, which amounts to 3.4% of the total genes under
study.
15. Diabetic with no parental history2 (reference) vs 
Diabetic with parental history (test sample) [DNPH2 vs 
DNPH]
The distribution of log fold change values was obtained
and the outliers were detected for the optimum cut-off
value (c*). Figure 20 shows the thresholds for 2-fold
change, thereby providing the up and down regulated
genes. Out of 3,940 outlier genes, 676 were detected as up
regulated, while 979 were detected as down-regulated
genes with respect to the individual with diabetic and no
parental history [2]. Thus, for diabetic with no parental
history [2] vs. diabetic with parental history comparison,
1,655 were found to be differentially expressed out of
39,400, which amounts to 4.2% of the total genes under
study. When figures 19 and 20 are compared, it is clear
that the differentially expressed genes between diabetics
with no parental history [subjects 1 and 2] vs diabetic with
parental history are very similar. This suggests that even
though subjects with diabetes with no parental history are
different the expressions of genes are closely similar when
compared with those seen in diabetics with parental his-
tory (see Figures 19 and 20).
Functional classification of differentially expressed genes
To determine biological significance of differentially
expressed genes, functional classification was performed
using Gene Ontology. Gene Ontology reports along with
Z-scores give statistical significance, indicating relative
representation up-regulated/down-regulated genes in
The thresholds for 2.18 and 2 fold change values Figure 18
The thresholds for 2.18 and 2 fold change values. The green 
spots are the differentially expressed outlier genes when one 
diabetic with no parental history [1] was compared with 
another diabetic with no parental history [2].
The thresholds for 2-fold change values Figure 19
The thresholds for 2-fold change values. The green spots are 
the differentially expressed outlier genes for diabetic with no 
parental history [1] vs. diabetic with parental history compar-
ison. Here the modified threshold was same as conventional 
2-fold change.Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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each function. To determine pathways associated with dif-
ferentially expressed genes, pathway analysis was per-
formed.
Gene Ontology Analysis
1. Diabetes with parental history vs Normal [DPH vs H]
Molecular Function
Genes involved in NADH dehydrogenase (ubiquinone)
activity, glutamate dehydrogenase [NAD(P)+] activity,
CDP-diacylglycerol-glycerol-3-phosphate-3-phosphtidyl-
transferase activity were upregulated in DPH with respect
to H. Genes involved in protein kinase B binding, enzyme
inhibitor activity, acyl-CoA oxidase activity, phosphati-
dylinositol transporter activity, acyltransferase activity
were downregulated in DPH with respect to H.
Biological Process
Genes involved in synaptic vesicle membrane organiza-
tion and biogenesis, polysaccharide metabolic process,
regulation of growth rate, nucleosome assembly were
upregulated in DPH with respect to H. Genes involved in
immune response, regulation of glycolysis were downreg-
ulated in DPH with respect to H.
Cellular Component
Genes localized in cohesin core heterodimer, oligosaccha-
ryl transferase complex, nucleosome, respiratory chain
complex II were upregulated in DPH with respect to H.
Genes localized in isoamylase complex, protein kinase
CK2 complex, proteasome activator complex, 6-phos-
phofructokinase complex were downregulated in DPH
with respect to H.
2. Diabetes without parental history1 vs Normal [DNPH1 vs H]
Molecular Function
Genes involved in hydroxyacylglutathione hydrolase
activity, NADH dehydrogenase (ubiquinone) activity,
GABA-B receptor activity, glutamate dehydrogenase
[NAD(P)+] activity, CDP-diacylglycerol-glycerol-3-phos-
phate-3-phosphatidyl transferase activity were upregu-
lated in DNPH1 with respect to H. Genes involved in
MHC class II receptor activity, structural constituent of
ribosome, Hsp70 protein binding, L-tyrosine transporter
activity, cyclin binding, arachidonate 5-lipoxygenase
activity were downregulated in DNPH1 with respect to H.
Biological Process
Genes involved in synaptic vesicle membrane organiza-
tion and biogenesis, plasma membrane organization and
biogenesis, polysaccharide metabolic process, regulation
of growth rate, regulation of pH were upregulated in
DNPH1 with respect to H. Genes involved in establish-
ment of cellular localization, cell activation, immune
response were downregulated in DNPH1 with respect to
H.
Cellular Component
Genes localized in vacuolar lumen, chromosome, nucleo-
some, proteasome activator complex were upregulated in
DNPH1 with respect to H. Genes localized in ferritin com-
plex, proton-transporting ATP synthase complex, cou-
pling factor F(o), ribosome, eukaryotic translation
elongation factor 1 complex, ubiquitin conjugating
enzyme complex were downregulated in DNPH1 with
respect to H.
3. Type 2 diabetes mellitus without parental history2 vs Normal 
[DNPH2 vs H]
Molecular Function
Genes involved in asparaginase activity, creatine: sodium
symporter activity, phosphomannomutase activity, gluta-
mate dehydrogenase [NAD(P)+] activity, basic amino
acid transporter activity, adenylosuccinate synthase activ-
ity were upregulated in D&NPH2 with respect to H. Genes
involved in structural constituent of ribosome, MHC class
II receptor activity, MHC class I receptor activity, L-tyro-
sine transporter activity, N-acylmannosamine kinase
activity were downregulated in D&NPH2 with respect to
H.
Biological Process
Genes involved in polysaccharide metabolic process, reg-
ulation of pH, aromatic compound biosynthetic process,
The thresholds for 2-fold change values Figure 20
The thresholds for 2-fold change values. The green spots are 
the differentially expressed outlier genes for diabetic with no 
parental history [2] vs diabetic with parental history. Here 
the modified threshold was same as conventional 2-fold 
change.
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regulation of growth rate, lipid glycosylation were upreg-
ulated in D&NPH1 with respect to H. Genes involved in
establishment of cellular localization, immune response,
ribosome biogenesis and assembly were downregulated
in D&NPH2 with respect to H.
Cellular Component
Genes localized in 4-aminobutyrate transaminase com-
plex, oligosaccharyl transferase complex were upregulated
in D&NPH1 with respect to H. Genes localized in ribos-
ome, Arp2/3 protein complex, eukaryotic translation
elongation factor 1 complex, small ribosomal subunit,
ferritin complex, mitochondrial outer membrane translo-
case complex were downregulated in D&NPH2 with
respect to H.
4. Obese vs Normal (O vs H)
Molecular Function
Genes involved in peptide deformylase activity, NADH
dehydrogenase (ubiquinone) activity, glutamate dehy-
drogenase [NAD(P)+] activity, phosphomannomutase
activity, transposase activity, carboxylic ester hydrolase
activity, glutamate decarboxylase activity, mannosyltrans-
ferase activity, transforming growth factor beta binding
were upregulated in O with respect to H. Genes involved
in glycolipid transporter activity, glycolipid binding, 3-
hydroxyisobutyrate dehydrogenase activity, 25-hydroxyc-
holecalciferol-24-hydroxylase activity were downregu-
lated in O with respect to H.
Biological Process
Genes involved in regulation of isoprenoid metabolic
process, polysaccharide metabolic process, regulation of
pH were upregulated in O with respect to H. Genes
involved in synaptic vesicle membrane organization and
biogenesis, cellular macromolecule catabolic process,
locomotion during locomotor behavior were downregu-
lated in O with respect to H.
Cellular Component
Genes localized in CAAX-protein geranylgeranyltrans-
ferase complex, intracellular organelle were upregulated
in O with respect to H. Genes localized in vesicle, eukary-
otic translation elongation factor 1 complex, perikaryon,
Golgi transport complex are downregulated in O with
respect to H.
5. Diabetes with parental history vs Obese [DPH vs O]
Molecular Function
Genes involved in glycolipid transporter activity, calmod-
ulin inhibitor activity, glycolipid binding, interleukin-22
receptor activity, oxygen transporter activity, antigen
binding, lactate dehydrogenase activity, glyoxylate reduct-
ase (NADP) activity, 25-hydroxycholecalciferol-24-
hydroxylase activity, glycerate dehydrogenase activity,
ubiquinol-cytochrome-c reductase activity were upregu-
lated in DPH with respect to O. Genes involved in amylo-
alpha-1, 6-glucosidase activity, 4-alpha-glucanotrans-
ferase activity, interleukin-8 receptor activity were down-
regulated in DPH with respect to O.
Biological Process
Genes involved in synaptic vesicle membrane organiza-
tion and biogenesis, response to stimulus, cellular macro-
molecule catabolic process were upregulated in DPH with
respect to O. Genes involved in regulation of isoprenoid
metabolic process, blastocyst growth, regulation of glyco-
lysis were downregulated in DPH with respect to O.
Cellular Component
Genes localized in vesicle hemoglobin complex, peri-
karyon, Golgi transport complex were upregulated in
DPH with respect to O. Genes localized in isoamylase
complex, CAAX-protein geranylgeranyltransferase com-
plex, NADPH oxidase complex, protein kinase CK2 com-
plex, MHC class I peptide loading complex, proteasome
activator complex are downregulated in DPH with respect
to O.
6. Genes that were similarly expressed both in diabetes and obesity 
[DPH and O]
Molecular Function
Genes involved in NADH dehydrogenase (ubiquinone)
activity, glutamate dehydrogenase [NAD(P)+] activity,
transposase activity, guanylate cyclase inhibitor activity
were upregulated both in diabetes and obesity. Genes
involved in hypoxanthine phosphoribosyltransferase
activity, structural constituent of ribosome, NADP bind-
ing, histone deacetylase activity were downregulated in
diabetes and obesity.
Biological Process
Genes involved in polysaccharide metabolic process, reg-
ulation of pH, tissue development, and diuresis were
upregulated both in diabetes and obesity. Genes involved
in regulation of hormone biosynthetic process, opsoniza-
tion were downregulated in diabetes and obesity.
Cellular Component
Genes localized in oligosaccharyl transferase complex,
cytoplasmic vesicle, ribosome are upregulated in diabetes
and obesity. Genes localized in small ribosomal subunit,
proton-transporting ATP synthase complex, coupling fac-
tor F(o) were downregulated in diabetes and obesity.
7. Obese vs overweight subjects with tendency towards Obesity (O 
vs HO)
Molecular Function
Genes involved in transforming growth factor beta bind-
ing, sodium: amino acid symporter activity, adenosylho-Lipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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mocysteinase activity, transferase activity, transferring acyl
groups, caspase activator activity, NAD(P)H oxidase activ-
ity,
steroid 21-monooxygenase activity, malate dehydroge-
nase (oxaloacetate-decarboxy-lating) (NADP+) activity,
glutamate decarboxylase activity were upregulated in O Vs
HO. Genes involved in creatine: sodium symporter activ-
ity, glycolipid transporter activity, glycolipid binding, 3-
hydroxyisobutyrate dehydrogenase activity, leukemia
inhibitory factor receptor activity, superoxide-generating
NADPH oxidase activity, chemokine receptor activity,
interleukin-22 receptor activity were downregulated in O
vs HO.
Biological Process
Genes involved in establishment of cellular localization,
cuticle biosynthetic process, hydrogen peroxide, biosyn-
thetic process, vesicle docking were upregulated in O vs
HO. Genes involved in synaptic vesicle membrane organ-
ization and biogenesis, response to stimulus, anatomical
structure development were downregulated in O vs HO.
Cellular Component
Genes localized in CAAX-protein geranylgeranyltrans-
ferase complex are upregulated in O vs HO. Genes local-
ized in Golgi transport complex, vesicle, oncostatin-M
receptor complex, perikaryon were downregulated in O vs
HO.
8. Diabetes with parental history vs diabetes without parental history 
(DPH vs DNPH1)
Molecular Function
Genes involved in MHC class II receptor activity, gamma-
aminobutyric acid: hydrogen symporter activity, chemok-
ine receptor activity, interleukin-4 receptor activity, inter-
leukin-7 receptor activity, arachidonate 5-lipoxygenase
activity, complement receptor activity were upregulated in
DPH vs DNPH1. Genes involved in ammonia ligase activ-
ity, transaldolase activity, 4-alpha-glucanotransferase
activity, choline: sodium symporter activity, interleukin-8
receptor activity were downregulated in DPH vs DNPH1.
Biological Process
Genes involved in cell activation, macromolecule biosyn-
thetic process, hydrogen peroxide biosynthetic process,
immune response, regulation of glycolysis were upregu-
lated in DPH Vs DNPH1. Genes involved in blastocyst
growth, aromatic compound biosynthetic process, nitric
oxide biosynthetic process, regulation of glycolysis were
downregulated in DPH vs DNPH1.
Cellular Component
Genes localized in ribonucleosidediphosphate reductase
complex, interleukin-18 receptor complex, interleukin-1
receptor complex, mitochondrion interleukin-5 receptor
complex were upregulated in DPH vs  DNPH1. Genes
localized in proteasome activator complex, isoamylase
complex, CAAX-protein geranylgeranyl-transferase com-
plex, protein kinase CK2 complex, oxoglutarate dehydro-
genase complex, MHC class I peptide loading complex
were downregulated in DPH vs DNPH1.
9. Diabetic with parental history of diabetes vs diabetic with no 
parental history of diabetes (DPH vs DNPH2)
Molecular Function
Genes involved in structural constituent of ribosome,
MHC class II receptor activity, ferroxidase activity,
NAD(P)H oxidase activity were upregulated in DPH vs
DNPH2. Genes involved in 4-alpha-glucanotransferase
activity, phospho-mannomutase activity, receptor signal-
ing protein tyrosine kinase activity were downregulated in
DPH vs DNPH2.
Biological Process
Genes involved in intracellular sequestering of iron ion,
ribosome biogenesis and assembly, hydrogen peroxide
biosynthetic process were upregulated in DPH vs DNPH2.
Genes involved in hemostasis, developmental growth,
lipid glycosylation, regulation of glycolysis were downreg-
ulated in DPH vs DNPH2.
Cellular Component
Genes localized in ribosome, ferritin complex are upregu-
lated in DPH vs DNPH2. Genes localized in CAAX-pro-
tein geranylgeranyltransferase complex, isoamylase
complex, apolipoprotein B mRNA editing enzyme com-
plex, lipopoly-saccharide receptor complex, proteasome
activator complex are downregulated in DPH vs DNPH2.
For easy understanding, a summary of the gene ontology
analysis data is given in Table 1.
Pathway Analysis
1. Diabetes with parental history vs Normal [DPH vs H]
Genes involved in inositol phosphate metabolism, starch
and sucrose metabolism, nitrogen metabolism, oxidative
phosphorylation, androgen and estrogen metabolism,
glycan biosynthesis and metabolism pathways, metabo-
lism of cofactors and vitamins pathways, MAPK signaling
pathway, ECM-receptor interaction, neuroactive ligand-
receptor interaction, regulation of actin cytoskeleton, cell
communication pathways, nervous system pathways,
neurodegenerative disorders pathways were upregulated
in DPH vs H. Genes involved in glycolysis/gluconeogene-
sis, propanoate metabolism, carbon fixation, biosynthesis
of steroids, fatty acid metabolism, histidine metabolism,
phenylalanine metabolism, tyrosine metabolism, urea
cycle and metabolism of amino groups, cell cycle, insulin
signaling pathway, PPAR signaling pathway, antigenLipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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processing and presentation were downregulated in DPH
vs H.
Molecular Function
Genes involved in NADH dehydrogenase (ubiquinone)
activity, glutamate dehydrogenase [NAD(P)+] activity,
CDP-diacylglycerol-glycerol-3-phosphate-3-phosphtidyl-
transferase activity were upregulated in DPH with respect
to H. Genes involved in protein kinase B binding, enzyme
inhibitor activity, acyl-CoA oxidase activity, phosphati-
dylinositol transporter activity, acyltransferase activity
were downregulated in DPH with respect to H.
Table 1: A summary of the gene ontology data with respect to molecular function is given here. Changes in the expression of genes 
concerned with biological processes and cellular components are given in the text.
S. No Comparison Up regulated genes Down regulated genes
1 DPH vs H NADH dehydrogenase (ubiquinone)
Glutamate dehydrogenase [NAD(P)+] CDP-diacylglycerol-glycerol-
3-phosphate-3-hosphitidltransferase
Protein kinase B binding
Acyl-CoA oxidase
Phosphatidylinositol transporter
Acyltransferase
2 DNPH1 vs H Hydroxyacylglutathione hydrolase
NADH dehydrogenase (ubiquinone)
GABA-B receptor Glutamate dehydrogenase [NAD(P)+] CDP-
diacylglycerol-glycerol-3-phosphate-3-phosphatidyl transferase
MHC class II receptor
Structural constituent of ribosome
Hsp 70 protein binding
L-tyrosine transporter Cyclin binding Arachidonate 
5-lipoxygenase
3 DNPH2 vs H Asparaginase activity
Creatine: sodium symporter
Phosphomannomutase activity
Glutamate dehydrogenase [NAD(P)+] basic amino acid transporter
Adenylosuccinate synthase
Structural constituent of ribosome
MHC class II receptor
MHC class I receptor
L-tyrosine transporter
N-acylmannosamine kinase
4O   vs H Deformylase
NADH dehydrogenase (ubiquinone) Glutamate dehydrogenase 
[NAD(P)+] Phosphomannomutase
Transposase
Carboxylic ester hydrolase
Glutamate decarboxylase Mannosyltransferase
Transforming growth factor beta binding
Glycolipid transporter activity Glycolipid binding
3-hydroxisobutyrate
Dehydrogenase
25-hydroxycholecalciferol-24-hydroxylase
5 DPH vs O Glycolipid transporter
Calmodulin inhibitor
Glycolipid binding
Interleukin-22 receptor
Oxygen transporter
Antigen binding
Lactate dehydrogenase
Glyoxylate reductase (NADP) activity
25-hydroxycholecalciferol-24-hydroxylase activity
Glycerate dehydrogenase
Ubiquinol-cytochrome-c reductase
Amylo-alpha-1, 6 Glucosidase
4-alpha-glucanotransferase
Interleukin-8 receptor activity
6 DPH and O NADH dehydrogenase (ubiquinone) Glutamate dehydrogenase 
[NAD(P)+] Transposase
Guanylate cyclase inhibitor
Hypoxanthine phosphoribosyltransferase Structural 
constituent of Ribosome
NADP binding, and histone deacetylase
7O   vs HO Transforming growth factor beta binding
Sodium: amino acid symporter
Adenosylhomocysteinase Transferase
Transferring acyl groups
Caspase activator
NAD(P)H oxidase
Steroid 21-monooxygenase
Malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+)
Glutamate decarboxylase
Creatine: sodium symporter activity
Glycolipid transporter
Glycolipid binding, 3-hydroxyisobutyrate 
dehydrogenase Leukemia inhibitory factor receptor 
Superoxide-generating NADPH oxidase
Chemokine receptor
Interleukin-22 receptor
8 DPH vs 
DNPH1
MHC class II receptor
Gamma-aminobutyric acid: hydrogen symporter
chemokine receptor Interleukin-4 receptor Interleukin-7 receptor 
Arachidonate 5-lipoxygenase
Complement receptor
Ammonia ligase
Transaldolase
4-alpha-glucanotransferase Choline: sodium 
symporter Interleukin-8 receptor
9 DPH vs 
DNPH2
Structural constituent of ribosome
MHC class II receptor
Ferroxidase
NAD(P)H oxidase
4-alpha-glucanotransferase
Phospho-mannomutase
Receptor signaling protein tyrosine kinaseLipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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2. Diabetes without parental history vs Normal [DNPH1 vs H]
Genes involved in carbohydrate metabolism pathways,
metabolism of cofactors and vitamins pathways, ubiqui-
tin mediated proteolysis, signal transduction pathways,
ECM-receptor interaction, neuroactive ligand receptor
interaction, regulation of actin cytoskeleton, cell cycle,
endocrine system pathways, nervous system pathways,
Huntington's disease were upregulated in DNPH1 vs H.
Genes involved in cell adhesion molecules (CAMs), anti-
gen processing and presentation were downregulated in
DNPH1 vs H.
3. Diabetes without parental history vs Normal [DNPH2 vs H]
Genes involved in carbohydrate metabolism pathways,
lipid metabolism pathways, glycan biosynthesis and
metabolism pathways, metabolism of cofactors and vita-
mins pathways, ubiquitin mediated proteolysis, signal
transduction pathways, signaling molecules and interac-
tion pathways, PPAR signaling pathway, GnRH signaling
pathway, nervous system pathways, development path-
ways, neurodegenerative disorders pathways were upregu-
lated in DNPH2 vs H. Genes involved in insulin signaling
pathway, immune system pathways were downregulated
in DNPH2 vs H.
4. Obese vs Normal [O vs H]
Genes involved in carbohydrate metabolism pathways,
lipid metabolism pathways, amino acid metabolism path-
ways, glycan biosynthesis and metabolism pathways,
metabolism of cofactors and vitamins pathways, ubiqui-
tin mediated proteolysis, signal transduction pathways,
neuroactive ligand-receptor interaction, nervous system
pathways, neurodegenerative disorders pathways are
upregulated in O vs H. Genes involved in cell adhesion
molecules (CAMs), cytokine-cytokine receptor interac-
tion, insulin signaling pathway, immune system path-
ways were downregulated in O vs H.
5. Diabetes with parental history vs Obese [DPH vs O]
Genes involved in Inositol phosphate metabolism, oxida-
tive phosphorylation, amino acid metabolism pathways,
ubiquinone biosynthesis, signal transduction pathways,
signaling molecules and interaction pathways, nervous
system pathways were upregulated in DPH vs O.
6. Diabetes with parental history vs diabetes without parental history 
(DPH vs DNPH1)
Genes involved in signal transduction, regulation of actin
cytoskeleton, antigen processing and presentation, com-
plement and coagulation cascades, axon guidance, Neuro-
degenerative disorders pathways were upregulated in
DPH vs DNPH1.
Genes involved in carbohydrate pathways were downreg-
ulated in DPH vs DNPH1.
7. Diabetes with parental history vs Diabetes with no parental 
history2 (DPH vs DNPH2)
Genes involved in oxidative phosphorylation, metabo-
lism of cofactors and vitamins pathways, immune system
pathways, nervous system pathways, metabolic disorders
pathways were upregulated in DPH vs  DNPH2. Genes
involved in lipid metabolism pathways, amino acid
metabolism pathways, glycan biosynthesis and metabo-
lism pathways, ubiquitin mediated proteolysis, signal
transduction pathways, signaling molecules and interac-
tion pathways, insulin signaling pathway, PPAR signaling
pathway were downregulated in DPH vs DNPH2.
Changes in the expression of genes involved in 
inflammatory response
Plasma levels of CRP, TNF-α, and IL-6, which are markers
of inflammation, are elevated in obesity, insulin resist-
ance, essential hypertension, type 2 diabetes, and CHD
both before and after the onset of these diseases [3-9]. In
view of this, we specifically looked at the genes that are
involved in inflammatory response in the present study.
The data given in Table 2 depicts the inflammatory genes
that were differentially expressed in obesity and type 2
diabetes mellitus.
Discussion
The incidence of obesity and type 2 diabetes mellitus and
with it the consequent metabolic syndrome X is increasing
throughout the world. It is estimated that by the year
2010, in the United States alone there may be about 50 to
75 million or more people with metabolic syndrome X.
One important feature of metabolic syndrome X is the
presence of insulin resistance. Subjects with abdominal
obesity, hypertension, type 2 diabetes, hyperlipidemias,
CHD, and stroke show insulin resistance and impaired
glucose tolerance (IGT). Plasma levels of inflammatory
markers such as CRP, TNF-α, and IL-6 are elevated in
obesity, insulin resistance, essential hypertension, type 2
diabetes, CHD, and metabolic syndrome X [3-9], suggest-
ing that all these disorders are associated with low-grade
systemic inflammation. This is supported by the results of
the present study wherein it was noted that genes involved
in inflammatory response are differentially expressed in
subjects with obesity and type 2 diabetes mellitus (see
Table 2).
Early stages of obesity, type 2 diabetes mellitus, hyperten-
sion, and metabolic syndrome X are characterized by
insulin resistance restricted to muscle tissue [16]. This
may be the reason why exercise is beneficial in the preven-
tion and treatment of insulin resistance since, it decreases
insulin resistance and enhances glucose utilization in the
muscles. Furthermore, exercise is anti-inflammatory in
nature [17,18]. Exercise not only decreases the levels of
inflammatory markers such as CRP, IL-6, and TNF-α butLipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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also simultaneously enhances the concentrations of anti-
inflammatory cytokines IL-4, IL-10 and TGF-β compared
to controls. IL-4, IL-10 and TGF-β are not only anti-
inflammatory in nature but also suppress the production
of pro-inflammatory cytokines IL-1, IL-2, and TNF-α [4].
Thus, under normal conditions there is a balance main-
tained between pro- and anti-inflammatory cytokines. In
addition, in experimental animals exercise significantly
reduced the magnitude of myocardial infarction and this
cardioprotective action paralleled the increase in manga-
nese superoxide dismutase (Mn-SOD) activity [19]. On
the other hand, administration of antisense oligo-deoxyri-
bonucleotide to Mn-SOD abolished this cardioprotective
action implying that enhancement of the activity of Mn-
SOD is crucial to exercise-induced cardioprotective action.
This increase in Mn-SOD activity is in response to exer-
cise-induced free radical generation suggesting that under
certain circumstances free radicals have highly beneficial
actions, especially when they are produced in response to
exercise. Pro-inflammatory cytokines enhance free radical
generation. It was noted that administration of antibodies
to TNF-α and IL-1 abolished the cardioprotective action of
exercise and activation of Mn-SOD, indicating that exer-
cise-induced increase in the production of pro-inflamma-
tory cytokines augment generation of free radicals that, in
turn, enhance Mn-SOD activity that is ultimately respon-
sible for the cardioprotective action of exercise. This is
supported by the observation that circulating levels of
extracellular SOD are lower in subjects with CHD [20].
These results are supported by the present observation
that in patients with type 2 diabetes mellitus genes con-
cerned with reactive oxygen species and pro-inflammatory
cytokines such as BCL2L1, MAPK1, IL8RA, and IL-6 were
up regulated whereas SOD2 was downregulated (see
Table 3). In addition, it was also noted that TGFBR1
(transforming growth factor-β receptor 1), which is an
anti-inflammatory cytokine that inhibits the production
of pro-inflammatory cytokines such as IL-6 and TNF-α
was found to be up regulated in type 2 diabetes, most
probably as a compensatory mechanism. These results
suggest that low-grade systemic inflammation plays a sig-
nificant role in the pathobiology of obesity, type 2 diabe-
tes mellitus, and metabolic syndrome X [1-9]. This is
supported by the observation that weight loss achieved by
type 2 diabetes subjects was associated not only with a
decrease in glycosylated hemoglobin (HbA1c), LDL cho-
lesterol, insulin resistance, plasminogen activator inhibi-
tor-1, CRP, IL-6, and TNF-α but also with significant
improvements in arterial stiffness [21] suggesting that
endothelial nitric oxide (eNO) production is increased
whereas oxidative stress is decreased. Thus, the results of
the present study and other investigations indicate the
genes concerned with inflammation and immune
response are differentially regulated in subjects with obes-
ity and type 2 diabetes mellitus.
In this context, it is important to note that acetylcholine
(ACh), the principal vagus neurotransmitter and an
Table 3: Pattern of gene expression observed in patients with 
type 2 diabetes mellitus with parental history (DPH) of diabetes 
vs healthy normal (H), and obese vs healthy.
Genes that have been down regulated in type 2 diabetes mellitus are:
MBL2, AKT1, ATP1A1, SOD2
Genes that have been up regulated in type 2 diabetes mellitus are:
ANXA1, NFKB2, GLUD1, BCL2L1, MAPK1, SOCS3, IRS2
Genes that have been up regulated in obese (O) compared to healthy 
(H) are:
IL8RA, TGFBR1, LITAF, IL-6, VEGFA
Table 2: Genes involved in inflammatory response that were differentially expressed in subjects with obesity and type 2 diabetes 
mellitus.
Condition Differentially expressed genes concerned with inflammation
Diabetic with family history vs Healthy individual 
(DPH vs H)
ALK, GCH1, IFIH1, IFIT1, IL11RA, ITGB2,MAP3K4, MMP19, MMP3, RPS27A, SLK, 
TNFRSF12A, UBC
Diabetic without family history vs healthy individual 
(DNPH1 vs H)
CCL3, CDKN1A, CXCL12, HLA-A, IL11RA, KRT8, LTB, MAP3K4, MMP10, 
MMP19, MMP20, MMP3, RPS27A, TNFSF10, UBC
Diabetic without family history Vs healthy individual 
(DNPH2 vs H)
CCL16, CCR8, CXCL11, CXCL12, FN1, GCH1, HLA-A, IL11RA, LTB, MMP19, 
MMP3, RHOA, S100A12, SLK, SYK, UBC
Obese vs Healthy (O vs H) CCL13, CXCL12, HLA-A, IL6, KRT8, MMP19, MMP27, MMP3, RPS27A, UBC
Diabetic with family history vs obesity (DPH vs O) ALK, CCL13, CCR4, CCR8, HGF, HLA-A, IFIT1, IL20, IL6, IL8RA, ITGB2, KRT8, 
MC1R, MMP20, MMP27, SLK, TNFRSF12A, UBC
Obese individual vs individual who is overweight (O vs HO) CCL13, CCL16, CCR8, HLA-A, IFIT1, IL6, KRT8, MC1R, MMP16, MMP27, 
TNFRSF12A, UBC
Diabetic with family history vs Diabetic without family history 
(DPH vs DNPH1)
ALK, CCL13, CCR8, CDKN1A, EDN1, FGF1, IFIT1, IL12RB1, IL20, IL22, IL2RG, 
IL8RA, ITGB2, MMP20, SLK, TNFRSF12A, UBC, XCR1
Diabetic with family history vs Diabetic without family 
History2 (DPH vs DNPH2)
ALK, BLR1, CCL15, CCL16, CCR7, CCR8, CXCL11, CXCL12, FN1, FTH1, GBP1, 
HLA-A, IFIT1, IL12A, ITGB2, KIT, LTB, MMP20, PPARD, RHOA, RPS27A, TAC1, 
TLR4, TNFAIP6, TNFRSF11ALipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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important neurotransmitter in the brain, is mostly con-
centrated in the brain, the spinal cord, and the rest of the
nerve cells in the body and on the muscles of the body.
The acetylcholine receptor modulates interactions
between the nervous system and the immune system. Fur-
thermore, the nervous system communicates with the
immune system in a bi-directional pathway. Nervous tis-
sues synthesize neuropeptides and cytokines and immune
cells serve as the molecular basis of neural-immune inter-
actions. Neural modulation can have both pro- and anti-
inflammatory effects. ACh is known to have anti-inflam-
matory actions and suppress the production of pro-
inflammatory cytokines [22] The cholinergic anti-inflam-
matory pathway signals through the efferent vagus nerve
and mediates its actions primarily by nicotinic acetylcho-
line receptors on tissue macrophages leading to decreased
NF-κB activation, preservation of high mobility group box
1 (HMGB1) nuclear localization and decreased produc-
tion of proinflammatory cytokines. In addition, ACh has
a regulatory role on serotonin, dopamine and other neu-
ropeptides [23,24], suggesting that a complex network of
interaction exists between these molecules in the regula-
tion of immune response and neurotransmission.
Since under normal physiological conditions sympathetic
and parasympathetic pathways demonstrate cross talk, it
is pertinent to note that phagocytes are capable of de novo
synthesis of catecholamines and blockade of α2-adrenore-
ceptors or catecholamine-generating enzymes suppressed
inflammation [25]. Thus, parasympathetic nervous sys-
tem suppresses inflammation by generating the anti-
inflammatory molecule ACh, whereas sympathetic nerv-
ous system enhances the inflammatory response by secret-
ing catecholamines. These results coupled with the
observation that serotonin, another neurotransmitter,
that has effects on behavior, mood, sleep, and appetite,
has a direct role in the development and treatment of type
2 diabetes is interesting [26,27]. For instance, mice lack-
ing the 5-HT2C receptor develop insulin resistance and
type 2 diabetes and later overeat and become obese,
whereas a drug that acts on 5-HT2C receptors improved
glucose tolerance without leading to reductions in food
intake or body weight by stimulating melanocyte-stimu-
lating hormone (α-MSH) in the brain's arcuate nucleus, a
portion of the hypothalamus that has a role in appetite
control. These evidences are supported by the results of
the present study wherein it was noted that genes involved
in neuroactive ligand-receptor interaction, nervous system
and neurodegenerative disorders pathways, axon guid-
ance and immune and inflammatory pathways are
altered.
In recent times since diet control, exercise, and drugs to
reduce obesity are largely unsuccessful, the Roux-en-gas-
tric bypass (RYGB) and other bariatric operations are
becoming one of the most common abdominal surgical
procedures in the USA [28]. RYGB produces on an average
49% to 65% weight loss within 2 to 5 years [29]. Besides
weight loss, RYGB ameliorates diabetes, hyperlipidemia,
and other obesity-related metabolic abnormalities
[30,31]. While working with a rat model of RYGB in diet-
induced obese rats, we observed that gastric bypass sur-
gery produces significant weight loss due to reduced
caloric intake with a reduction in meal size and meal
number, accompanied by a decrease in serum glucose,
insulin, leptin, triglyceride concentrations, and subcuta-
neous abdominal fat compared to the obese [32].
Further studies revealed that weight loss achieved by
RYGB is in part due to a decrease in NPY (neuropeptide Y)
in ARC (arcuate nucleus f hypothalamus), pPVN (parvo-
cellular part of paraventricular nucleus of hypothalamus),
and mPVN (magnocellular part of PVN) and an increase
in  α-MSH in ARC, pPVN, and mPVN compared with
obese controls. 5HT-1B-receptor in pPVN and mPVN
increased in RYGB and PF (pair fed) compared to obese
control [33]. These results emphasize the fact that weight
loss seen after RYGB and diet control is due to specific
changes in hypothalamic peptides. Serotonin innervation
is widely distributed in the hypothalamus and it inner-
vates NPY neurons both in the ARC and PVN. Serotonin
has a suppressive effect on food intake. Thus, weight loss
seen in RYGB and diet control groups could be attributed
to alterations in the concentrations of specific hypotha-
lamic signaling peptides that regulate appetite, food
intake and satiety. Even in tumor bearing anorectic rats,
which showed significant weight loss due to tumor bur-
den, similar results were seen: an increase of serotonin in
PVN and VMN (ventromedial nucleus of hypothalamus)
and a concomitant decrease of dopamine in PVN, VMN
and LHA (lateral hypothalamus), and of NPY in LHA,
VMN and PVN; a decrease in NPY in ARC and of POMC
(proopiomelanocortin) in ARC and PVN [33,34] and
these abnormalities reverted to normal after tumor resec-
tion. In this context, it is noteworthy that even the concen-
trations of IL-6 and TNF-α were found to be elevated in
ARC in tumor-bearing rats. These results emphasize the
close interaction(s) between neurotransmitters, inflam-
matory molecules, and obesity and type 2 diabetes melli-
tus [35].
Obviously the present results need to be verified using a
larger sample size, by estimating the concentrations of the
specific proteins of the genes expressed, and studying
more closely the interaction(s) between the nervous sys-
tem, hypothalamic peptides and neurotransmitters, pro-
and anti-inflammatory cytokines, and their relationship
to appetite, satiety, development of obesity and type 2 dia-
betes mellitus. It is also likely that there could be individ-
ual variations in the expression of various genesLipids in Health and Disease 2007, 6:35 http://www.lipidworld.com/content/6/1/35
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concerned with appetite, satiety, and inflammation and
this need to be taken into consideration while assigning
importance to the degree of expression of some of these
genes. Such variations in the expression of genes could be
detected only by performing studies in a larger sample
size. Nevertheless, the results of the present study suggest
that there are significant differences in the expression of
various genes concerned with carbohydrate, lipid, and
protein metabolism, ubiquitin mediated proteolysis, sig-
nal transduction pathways, neuroactive ligand-receptor
interaction, nervous system pathways, cell adhesion mol-
ecules, cytokine-cytokine receptor interaction, insulin sig-
naling and immune system pathways, oxidative
phosphorylation, and PPAR signaling pathways in sub-
jects with obesity and type 2 diabetes compared to nor-
mal.
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